



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|---------------------|-------------------------------|
| 09/935,417 | 08/22/2001 | Leon V. Rudakov | 52200-8006.US01 | 9486 |
| 22918 | 7590 | 12/15/2004 | | |
| PERKINS COIE LLP P.O. BOX 2168 MENLO PARK, CA 94026 | | | | EXAMINER LAM, ANN Y |
| | | | | ART UNIT 1641 PAPER NUMBER |

DATE MAILED: 12/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | | |
|------------------------------|------------------------|---------------------|--|
| Office Action Summary | Application No. | Applicant(s) | |
| | 09/935,417 | RUDAKOV ET AL. | |
| | Examiner | Art Unit | |
| | Ann Y. Lam | 1641 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 01 September 2004.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 17-19 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 17-19 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____. |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____. | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 17 is rejected under 35 U.S.C. 102(e) as being anticipated by Alcime et al., 5,632,772.

As to claims 17 and 18, Alcime discloses an expandable support (stent, for example, reference 32, column 6, line 48) from having first and second end portions, a porous polymer sleeve (liner, for example, reference 34, column 6, line 53-55) having inner and outer surfaces, and a coating of a cell adhesion peptide (column 13, lines 56-61) carried on and attached to at least one of the inner and outer surfaces of the polymer sleeve for enhancing endothelial cell growth on the polymer sleeve.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 18 is rejected under 35 U.S.C. 103(a) as being unpatentable over Alcime et al., 5,632,772, in view of Bhatnagar, 5,958,428.

Claim 18 is a product by process claim so no weight is given to the process limitations. The product is substantially disclosed by Alcime (see above.) Additionally, Alcime teaches that the stent is made of metal (col. 13, line 18 and 24.) However, Alcime does not specifically disclose linkers/spacers forming covalent bonds with the cell-adhesion peptides as a means to link the peptides to the substrate.

Bhatnagar discloses use of spacer arms to facilitate binding of peptides to a substrate, including glass, plastics, and metallics, (col. 10, lines 24-32, and lines 51-53.) It would have been obvious to one of ordinary skill in the art to provide spacers/linkers as taught by Bhatnagar in order to link the peptides to the metallic Alcime substrate, as a well known and conventional means of attaching biomolecules to a substrate.

Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Alcime et al., 5,632,772, in view of Brown et al., 6,071,305, and further in view of Bhatnagar, 5,958,428.

Alcime et al. disclose the invention substantially as claimed (see above), except for the cell-adhesion peptide having the amino acid sequence presented as SEQ ID NO:1. Alcime teaches an expandable stent for treatment of blood vessels, wherein the stent includes therapeutic drugs such as heparin, column 13, lines 56-61.

Brown et al. teaches the use of therapeutic drugs such as heparin or collagen on a stent (column 2, lines 38-52, column 5, line 17 and 26).

Bhatnagar teaches that collagen functions as a structural protein of tissues and that it is the major fibrous element in blood vessels, see column 1, lines 50-53, and that collagen participates in physiological interactions which include formation of complexes with other macro-molecules such as fibronectin and the modulation of cell proliferation, see column 2, lines 24-31. Bhatnagar further discloses that collagen appears to cause adverse reactions within the body, and thus synthetic peptides are provided that mimic the cell binding domain of collagen, see column 3, lines 21-32. Bhatnagar teaches that the synthetic peptide has the amino acid sequence as disclosed in column 3, lines 42-43, which is the same amino acid sequence as Applicant's claimed SEQ ID NO:1.

Since both Alcime and Brown both teach the use of providing a therapeutic drug such as heparin or other drugs on a stent, and Brown further teaches that the drug may also be collagen, it would have been obvious to provide collagen as the therapeutic drug in the Alcime stent with the polymer sleeve.

Furthermore, it would have been obvious to provide, on the Alcime stent, the synthetic peptide disclosed by Bhatnagar, as an alternative to collagen, as would be desirable to obtain the same therapeutic effect as collagen but without the adverse effects of collagen, as taught by Bhatnagar.

Response to Arguments

Applicant's arguments filed September 1, 2004 have been fully considered but they are not persuasive.

Applicant alleges that neither Alcime nor Brown disclose a "coating", nor a "coating....for enhancing endothelial cell growth", and that the Bhatnagar device is not concerned with any device like the subject invention.

In response, Examiner reasserts that the "surface treatment" taught by Alcime in column 13, lines 56-60, is a coating. Moreover, although Alcime does not teach the specific drug claimed, Brown teaches a stent to deliver drugs for a variety of medical treatments including regulating tissue growth and enhancing healing of tissue (col. 5, lines 11-12). Brown specifically teaches that such drugs may be collagen (col. 5, line 26.) It would have been obvious that the Alcime stent, which was disclosed as being used to locally deliver drugs in general, can be used to deliver drugs such as collagen in order to regulate tissue growth and enhance healing of tissue as taught by Brown. Moreover, Bhatnagar further teaches that collagen, when used as a drug for regulation of tissue growth (col. 2, lines 24-31), can cause adverse reactions within the body, and thus synthetic peptides which mimic the cell binding domain of collagen can be alternatively used, see column 3, lines 21-32. The synthetic peptide disclosed by Bhatnagar in column 3, lines 42-43, is the same amino acid sequence as Applicant's claimed SEQ ID NO:1.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Y. Lam whose telephone number is 571-272-0822. The examiner can normally be reached on M-Sat 11-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A.L.



Christopher L. Chin

CHRISTOPHER L. CHIN
PRIMARY EXAMINER
GROUP 1641

12/12/07